TD Cowen initiated coverage on Grace Therapeutics with a new price target
$GRCE
Biotechnology: Pharmaceutical Preparations
Health Care
TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | $12.00 | Buy | TD Cowen |
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract of the Company's Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (the STRIVE-ON trial–NCT05995405) has been accepted for presentation as a late breaking trial at the Society of Vascular and Interventional Neurology (SVIN) annual meeting, to be held November 19-22, 2025 in Orlando, FL.
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced it has secured approximately $4.0 million in additional funding through exercises of common warrants that were previously issued in a private placement that the Company closed in September 2023. The Company issued 1,345,464 new shares of common stock at an exercise price of $3.003 per share. The remaining 1,1
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aSAH patients, today announced that results from its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (the STRIVE-ON trial–NCT05995405) were presented at the 2025 Neurocritical Care Society annual meeting, held in Montreal, Quebec, Canada September 18-21, 2025. In an oral presentation titled Safety and Tolerability of GTx-104 (Nimodipine Injection for I.V. Infusion
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu
SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)